MediLink Therapeutics
China - Suzhou
BiotechnologyFocus: ADC
MediLink Therapeutics is a life sciences company focused on ADC.
Oncology
Funding Stage
SERIES B
Total Funding
$70M
Open Jobs
0
Pipeline & Clinical Trials
Enhanced Body-Swap for Anorexia Nervosa
Eating DisordersClinical Trials (1)
NCT06799962AI and VR Devices for Eating Behavior Rehabilitation
N/APhase 1
Clinical Trials (1)
NCT05653752A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer
Phase 1Phase 1
Clinical Trials (1)
NCT06394414A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors
Phase 1YL217
Advanced Solid TumorClinical Trials (1)
NCT06859762A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
Phase 1Phase 1
Phase 1
Phase 1/2
Clinical Trials (1)
NCT07111520A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
Phase 1/2YL201
Advanced Solid TumorClinical Trials (1)
NCT05434234A Study of YL201 in Patients With Advanced Solid Tumors
Phase 1/2YL201 for Injection
Advanced Solid TumorClinical Trials (1)
NCT06057922A Study YL201 in Patients With Selected Advanced Solid Tumors
Phase 1/2YL202 for injection; Toripalimab injection
Advanced Solid TumorsClinical Trials (1)
NCT07169994A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Phase 1/2YL242
Advanced Solid TumorClinical Trials (1)
NCT07197827A Study of YL242 in Subjects With Advanced Solid Tumors
Phase 1/2intravenous
Advanced Solid TumorsClinical Trials (1)
NCT06459973A Clinical Study of YL205 in Patients With Advanced Solid Tumors
Phase 1/2Phase 1/2
Clinical Trials (1)
NCT07258979A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
Phase 1/2Phase 1/2
YL202 should be intravenously infused
NSCLCClinical Trials (1)
NCT06107686A Study of YL202 in Selected Patients With Advanced Solid Tumors
Phase 2Phase 2
Clinical Trials (1)
NCT07202364A Study of YL202 in Patients With Advanced Solid Tumors
Phase 2YL202 should be intravenously infused
Locally Advanced or Metastatic Breast CancerClinical Trials (1)
NCT06439771A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC
Phase 2YL201 for Injection
Metastatic Castration-resistant Prostate Cancer (mCRPC)Clinical Trials (1)
NCT06241846A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
Phase 2Phase 3
Clinical Trials (1)
NCT06629597A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma
Phase 3Phase 3
Clinical Trials (1)
NCT06612151A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer
Phase 3Phase 3
Clinical Trials (1)
NCT07416994Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer
Phase 3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 18 clinical trials